I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter @theroberthart or email me at [email protected]
Pfizer and BioNTech plan to ask regulators to give their Covid-19 vaccine emergency authorization for use in kids aged five and up, the companies said Monday, after announcing the first set of promising results from a major vaccine trial in this age group.gettyEarly findings from the trial, which involved 2,268 children aged five to 11 years old and has not been peer reviewed, showed the vaccine produced a “strong immune response” one month after the second dose, the companies said.
The children were given shots one third the strength of what is used for those aged 12 and up, but the study indicated comparable immune responses to 16 to 25 year olds receiving the standard two-dose regimen, the companies said. The vaccine is “safe” and “well tolerated” in the younger age group, the companies said, and side effects are also similar to those experienced by 16 to 25 year olds, including injection site pain, fever, fatigue and chills.
Pfizer CEO Albert Bourla said the results provide a “strong foundation” for the company to seek authorization for the vaccine’s use in children five to 11 years old, adding it plans to submit the findings to regulators like the U.S. Food and Drug Administration and the European Medicines Agency as soon as possible.
High-level findings from other parts of the trial, which cover children aged six months to five years, are expected by the end of the year, the companies said, and data from the full trial will be submitted for peer review and publication in a scientific journal. 5.3 million. That’s how many children have tested positive for Covid-19 in the U.S. since the pandemic began, as of September 9,
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer says COVID-19 vaccine works in kids ages 5 to 11, will seek authorizationPfizer said its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon.
Read more »
Pfizer Prepares To Seek U.S., EU Approval For Its Covid Vaccine In Kids As Young As FiveI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Read more »
Pfizer recalls all lots of anti-smoking drug Chantix over carcinogen presenceLong-term ingestion of the drug can lead to a 'potential increased cancer risk in humans, but there is no immediate risk to patients taking this medication.'
Read more »
Pfizer says COVID-19 vaccine works in kids ages 5 to 11Pfizer said Monday its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon -- a key step toward beginning vaccinations for youngsters. The vaccine made by Pfizer and its German partner BioNTech already is available for anyone 12 and older.
Read more »
Pfizer says COVID-19 vaccine safe, effective for kids ages 5 to 11Pfizer and BioNTech released data saying its vaccine is safe and effective for kids 5-11.
Read more »